Study Evaluating Safety and Tolerability of Ascending Multiple Dose of SLV-313 in Schizophrenia Patients
NCT ID: NCT00581243
Last Updated: 2022-05-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
32 participants
INTERVENTIONAL
2008-01-01
2008-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Evaluating Multiple Ascending Dose in Schizophrenia Patients
NCT00620568
In-Patient Study In Schizophrenic Patients
NCT00197093
Clinical Trial of AVL-3288 in Schizophrenia Patients
NCT02978599
Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy Subjects
NCT01851603
A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable Schizophrenia
NCT01812642
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
2 mg SLV-313 SR (fixed dose)
SLV-313 SR
sustained relase tablets taken once daily for 14 days
2
5 mg SLV-313 SR (fixed dose)
SLV-313 SR
sustained relase tablets taken once daily for 14 days
3
10 mg SLV-313 SR (fixed dose)
SLV-313 SR
sustained relase tablets taken once daily for 14 days
4
xx mg SLV-313 SR (titration)
SLV-313 SR
sustained relase tablets taken once daily for 14 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SLV-313 SR
sustained relase tablets taken once daily for 14 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women, aged 18-50 years old
Exclusion Criteria
* Non-pregnant women, aged 18-50 years old
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Solvay Pharmaceuticals
INDUSTRY
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Wyeth is now a wholly owned subsidiary of Pfizer
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3170A1-01001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.